iCAD to Present at the Spring Into Action - Best Ideas Virtual Investor Conference on May 17th, 2022
NASHUA, NH / ACCESSWIRE / May 12, 2022 / iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will present at the Spring Into Action - Best Ideas …
NASHUA, NH / ACCESSWIRE / May 12, 2022 / iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will present at the Spring Into Action - Best Ideas Virtual Investor Conference, which is being held virtually on May 16th - 20th, 2022.
Stacey Stevens, President and CEO of iCAD, Inc. will present on Tuesday, May 17, 2022, from 11:30 to 11:55 a.m. EST. iCAD management will be available for one-on-one meetings during the conference. The presentation will be webcast live and available for replay here: https://www.webcaster4.com/Webcast/Page/2882/45573
To receive additional information, request an invitation or schedule a one-on-one meeting, please email firstname.lastname@example.org.
Investors can register here.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD® is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expected benefits of ProFound AI®, the benefits of the Company's products, external factors affecting the market for our products, behavior of clients and prospective clients, and future prospects for the Company's technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company's ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe," "demonstrate," "intend," "expect," "estimate," "will," "continue," "anticipate," "likely," "seek," and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.
Jessica Burns, iCAD
iCAD Investor Relations
SOURCE: iCAD, Inc.
View source version on accesswire.com: